Investigational Drug Information for NNZ-2591
✉ Email this page to a colleague
What is the development status for investigational drug NNZ-2591?
NNZ-2591 is an investigational drug.
There have been 5 clinical trials for NNZ-2591.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 30th 2023.
The most common disease conditions in clinical trials are Syndrome, Chromosome Disorders, and Chromosome Deletion. The leading clinical trial sponsors are Neuren Pharmaceuticals Limited and [disabled in preview].
There are seven US patents protecting this investigational drug and thirty-five international patents.
Summary for NNZ-2591
| US Patents | 7 |
| International Patents | 35 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2023-06-30) |
| Vendors | 16 |
Recent Clinical Trials for NNZ-2591
| Title | Sponsor | Phase |
|---|---|---|
| An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) | Neuren Pharmaceuticals Limited | Phase 2 |
| An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome | Neuren Pharmaceuticals Limited | Phase 2 |
| An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) | Neuren Pharmaceuticals Limited | Phase 2 |
Clinical Trial Summary for NNZ-2591
Top disease conditions for NNZ-2591
Top clinical trial sponsors for NNZ-2591
US Patents for NNZ-2591
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| NNZ-2591 | ⤷ Sign Up | Cyclic G-2Allylproline in treatment of Parkinson's disease | Neuren Pharmaceuticals, Ltd. (Auckland, NZ) | ⤷ Sign Up |
| NNZ-2591 | ⤷ Sign Up | Neuroprotective bicyclic compounds and methods for their use | Neuren Pharmaceuticals Limited (Auckland, NZ) | ⤷ Sign Up |
| NNZ-2591 | ⤷ Sign Up | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | ⤷ Sign Up | |
| NNZ-2591 | ⤷ Sign Up | Osmotic device containing amantadine and an osmotic salt | Osmotica Kereskedelmi es Szolgaltato KFT (Budapest, HU) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for NNZ-2591
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| NNZ-2591 | Cyprus | CY1117211 | 2023-09-03 | ⤷ Sign Up |
| NNZ-2591 | Denmark | DK1664050 | 2023-09-03 | ⤷ Sign Up |
| NNZ-2591 | European Patent Office | EP1664050 | 2023-09-03 | ⤷ Sign Up |
| NNZ-2591 | Spain | ES2564803 | 2023-09-03 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
